Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & ToxicityAndrew J. Portuguese, Jordan Gauthier, Lorenzo Iovino et al.|Transplantation and Cellular Therapy|2024Cited by 9
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J. Portuguese, Jordan Gauthier, Jennifer J. Huang et al.|Haematologica|2025Cited by 4
Risk Factors for Pre-CAR-T Attrition Among Large B-Cell Lymphoma (LBCL) PatientsNatalie Wuliji, Andrew J. Portuguese, Rahul Banerjee et al.|Transplantation and Cellular Therapy|2024Cited by 2
Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical CenterAndrew J. Portuguese, Andrew J. Cowan, Mahnoosh Taheri et al.|Blood|2024Cited by 0